Press releases

18 December, 2013

Regulatory

NeuroVive—SEK 35 m private placement complete, more information on forthcoming SEK 75.8 m rights issue

The private placement reported to the market on 20 November 2013 and approved by the Extraordinary General Meeting (EGM) on 13 December 2013 is now complete.

13 December, 2013

Regulatory

Report from Extraordinary General Meeting

On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majori ...

3 December, 2013

NeuroVive’s participation at keynote shareholders’ event in Gothenburg, and interview with our CEO.

On 25 November, Mikael Brönnegård from NeuroVive was a speaker at a keynote investment event in Gothenburg, arranged by the Swedish Association of Share Investors at the Swedish Exhibition & Conferenc ...

21 November, 2013

Regulatory

Correction: NeuroVive proposes resolution on private placement and rights issue totaling approximately SEK 111 m

The news release of 20 November at 5:55 p.m. stated the subscription period for the Rights Issue as 13-27 January 2013. The correct dates should be 13-27 January 2014.

20 November, 2013

Regulatory

NeuroVive: Interim Report 1 Jan. 2013 till 30 Sep. 2013

Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators

20 November, 2013

Regulatory

NeuroVive proposes resolution on private placement and rights issue totaling approximately SEK 111 m

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (publ), (the "Company") decided to convene an Extraordinary General Meeting (EGM) and to propose that the Meeting approves a ...

9 October, 2013

Regulatory

Catharina Johansson appointed new CFO, effective 1 December

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has appointed Catharina Johansson as the company's new CFO. She will take up her position on 1 December. This appointment ...

23 August, 2013

Regulatory

NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...

12 June, 2013

Regulatory

NeuroVive signs collaboration agreement with Isomerase Therapeutics and receives the first milestone payment from Sihuan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from ...

5 June, 2013

Regulatory

First patient recruited to clinical phase II study for treatment of traumatic brain injury

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company ́s drug candidate NeuroSTAT® for the ...

29 May, 2013

NeuroVive: European phase III study approaches its final stage

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that the ongoing international multicenter phase III study on the company ́s drug candidate CicloMulsion® (the C ...

24 May, 2013

Regulatory

NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013

The listing on Nasdaq OMX creates possibilities for the future